Does the nicotine metabolite ratio moderate smoking cessation treatment outcomes in real-world settings? A prospective study by Shahab, L et al.
Does the nicotine metabolite ratio moderate smoking
cessation treatment outcomes in real-world settings?
A prospective study
Lion Shahab1,2 , Linda Bauld2,3 , Ann McNeill2,4 & Rachel F. Tyndale5
Department of Behavioural Science and Health, University College London, London, UK,1 UK Centre for Tobacco and Alcohol Studies, Nottingham, UK,2 Usher Institute
of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK,3 Addictions Department, Institute of Psychiatry, Psychology and Neuroscience,
King’s College London, London, UK4 and Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH) and Departments of
Psychiatry and Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada5
ABSTRACT
Background and aims In smoking treatment trials comparing varenicline with transdermal nicotine replacement ther-
apy (NRT), stratiﬁed by nicotine metabolite (3-hydroxycotinine/cotinine) ratio (NMR), the relative beneﬁt of varenicline is
greater among normal rather than slow metabolizers. This study tested if the relative effectiveness of varenicline and NRT
is associated with NMR status in a natural treatment setting. A secondary aim was to test if this relationship is moderated
by behavioural support. Design Prospective observational multi-centre study with 4-week and 52-week follow-up.
Setting Nine English Stop Smoking Services (SSS). Participants Data came from 1556 smokers (aged ≥ 16 years) at-
tending SSS between March 2012 and March 2013. Interventions Participants received pharmacotherapy together
with behavioural support.Measurements The primary outcome was carbon monoxide-veriﬁed continuous abstinence
at both follow-up times. Main explanatory variables were (1) NMR status [slow (NMR < 0.31, n = 451) versus normal
(NMR ≥ 0.31, n = 1105) metabolizers]; (2) pharmacotherapy (varenicline versus NRT) and (3) behavioural support (in-
dividual versus group-based treatment). Analyses adjusted for baseline socio-demographic, SSS, mental/physical health
and smoking characteristics. Findings Of participants, 44.2% [95% conﬁdence interval (CI) = 41.7–46.6%] and 8.0%
(95%CI = 6.8–9.5%) were continuously abstinent at 4 and 52weeks. Varenicline wasmore effective than NRTat 4 weeks
(P < 0.001) but only marginally so at 52 weeks (P = 0.061). There was no or inclusive evidence that NMR status mod-
erated relative efﬁcacy of varenicline and NRT at 4- [P = 0.60, Bayes factor (BF) = 0.25] or 52-week follow-ups (P = 0.74,
BF = 0.73). However, this relationship was moderated by behavioural support (p = 0.012): the relative beneﬁt of
varenicline over NRT at 52-week follow-up was greater in slow, not normal, metabolizers receiving group rather than
individual support (P = 0.012). Conclusions In a real-world setting, the nicotine metabolite ratio status of treatment-
seeking smokers does not appear to contribute substantially to the differential effectiveness of varenicline and nicotine
replacement therapy in Stop Smoking Services, when both pharmacotherapy and behavioural support are self-selected.
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INTRODUCTION
Despite the existence of effective behavioural and pharma-
cological smoking cessation interventions, most treatment-
seeking smokers will still fail even with additional support
[1–7]. Given our increasing understanding of the molecu-
lar genetics of smoking and evidence of substantial
heritability for tobacco addiction [8,9], one option to im-
prove cessation rates is to prescribe pharmacological treat-
ment on the basis of genetically informed biomarkers
[10,11]. The rationale is that the same genetic factors
which predispose an individual to nicotine addiction may
also moderate the response to pharmacotherapy [12].
One such candidate biomarker is the nicotine metabolite
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ratio (NMR), calculated as the quotient of two major me-
tabolites of nicotine [30hydroxycotinine (3HC) and cotin-
ine], which functions as a phenotypical surrogate of
nicotine clearance [13].
The liver enzyme CYP2A6, part of the cytochrome
P450 enzyme system, is largely responsible for the metab-
olism of nicotine into cotinine [14], and exclusively respon-
sible for cotinine’s metabolism into 3HC [15]. The
encoding gene CYP2A6 is highly polymorphic, and has
been associated with nicotine dependence and smoking be-
haviour [16,17]. However, as a phenotypical marker, NMR
has an advantage over genotypical markers by incorporat-
ing genetic, environmental and demographic inﬂuences on
nicotine metabolism [18,19]. It can also be measured eas-
ily and non-invasively from saliva and urine as well as
blood [20]. Both NMRand categorized NMR (into slow ver-
sus normal/fast metabolizers) have been shown to be stable
over time in ad-libitum [21,22] and treatment-seeking
smokers [23], and independent of smoking patterns and
time since last cigarette, given the comparatively long
half-lives of cotinine and 3HC [13,21]. The NMR appears
suitable for one-time assessments, correlates well with
clearance of nicotine that is administered orally or intrave-
nously [13,24] and is not affected by time of sampling
[21,25]. Although NMR varies somewhat with sex [26],
race [27], age [28] and bodymass index [22], it is relatively
consistent across different socio-demographic and health
characteristics, with such factors accounting for less than
8–9% in variance of NMR [19,29,30]. However, NMR
can be inﬂuenced by both environmental inducers and in-
hibitors, some of which can be transitory [19].
NMR is related to smoking behaviour in a number of
ways. Smokers with a higher NMR, who therefore metabo-
lize nicotine more quickly, also tend to be heavier smokers
[31]. In addition, faster metabolizers appear to smoke ciga-
rettes more intensely, resulting in higher exposure to
tobacco-related carcinogens [32]. However, the association
of NMR with nicotine dependence and withdrawal symp-
toms is less clear-cut, with some but not all studies ﬁnding
an association of greater dependence and more severe
withdrawal symptoms among faster metabolizers
[20,31]. Similarly, data on the association of NMR with
smoking cessation outcomes aremixed. Studies of pharma-
cological treatments have shown that slow metabolizers
tend to have lower relapse rates than normal/fast
metabolizers when treated with nicotine patch [33,34]
with placebo [35], or irrespective of treatment provided
[36], whereas other studies have found an opposite pat-
tern, with lower relapse rates among faster metabolizers
using nicotine replacement therapy (with metabolism de-
ﬁned by genotype) [37] or when not using any treatment
(with metabolism deﬁned by NMR) [38]. Still others ﬁnd
no difference in the effect of NMR on treatment with NRT
but higher overall abstinence rates among slow
metabolizers [39]. Reﬂecting this uncertainty in the litera-
ture, a recent Cochrane review was inconclusive with re-
gard to the superior efﬁcacy of speciﬁc pharmacological
treatment as a function of NMR [40].
The most rigorous assessment of the potential role of
NMR for personalizing pharmacotherapy for smoking ces-
sation comes from a recent placebo-controlled clinical trial
which prospectively randomized to treatment arm
(varenicline or NRT patch) by NMR stratiﬁcation [41].
Clinical trials directly comparing varenicline with NRT
have shown that varenicline is generally more effective
than NRT [42]. In contrast, this study found a signiﬁcant
NMR × treatment interaction, suggesting that varenicline
was relatively more effective than transdermal NRT only
for normal/fast (6-month abstinence rates: 22 versus
13.6%) but not slow metabolizers (19.1 versus 21.6%).
The implication is that in future normal/fast metabolizers
should preferentially be prescribed varenicline and slow
metabolizers transdermal NRT. However, given conﬂicting
evidence to date and a call for replication and validation
of NMR studies in different contexts [43], extension of
these ﬁndings to other populations (treatment-seeking
smokers), different operationalizations of NMR and geo-
graphic locations is now required. This is particularly im-
portant as there are well-known differences in the
treatment provision and participant characteristics for
clinical trials compared with general population studies
[44], and consequent failures to replicate trial ﬁndings,
e.g. for smoking cessation treatments [45], based on real-
world data. We have shown previously that the choice of
pharmacotherapy in real-world settings [Stop Smoking
Services (SSS) in England] is not inﬂuenced by NMR status,
suggesting that there is scope to optimize treatment alloca-
tion [30]. However, in this context it is also important to
consider other non-pharmacological treatment factors, as
the uptake of behavioural support was shown to differ as
a function of NMR status, with normal metabolizers being
less likely to choose group over individual support than
slow metabolizers [30]. The importance of this needs to
be explored further.
In a large sample of treatment-seekers in the United
Kingdom, the present study therefore aimed to:
1 test whether NMR status (slow versus normal) moder-
ates the short- and long-term effectiveness of NRT
compared with varenicline for smoking cessation in
real-world settings;
2 assess whether results are consistent across different
operationalizations of NMR (as a continuous measure
or based on quartiles) or when restricting pharmaco-
therapy to varenicline and transdermal nicotine patch
alone; and
3 test whether this relationship is moderated by the type
of behavioural treatment (individual or group support)
received.
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METHODS
Design
This is a prospective observational study [Evaluating Long-
term Outcomes of NHS Stop Smoking Services (ELONS]
carried out in nine SSS across three regions of England
(North, South and Midlands). Participants were recruited
into the study at their ﬁrst visit, at which stage they pro-
vided saliva samples to determine NMR status, and were
followed-up via the SSS until 4 weeks post their quit date
to determine short-term continuous abstinence. Partici-
pants conﬁrmed to be abstinent at 4-week follow-up were
re-contacted by the research team at 52 weeks post-quit
to determine long-term continuous abstinence.
Participants and procedure
The ELONS study recruited and consented 3044 partici-
pants, who were not pregnant and aged 16 or above,
who accessed nine SSS in England between March 2012
and March 2013 and who set a ﬁrm quit date.
For the purpose of this analysis, participants who
elected to not receive pharmacotherapy, only bupropion,
orwho chose combination therapy of NRTwith varenicline
or bupropion were excluded. Full details on ELONS meth-
odology can be found elsewhere [46]. Of the ELONS partic-
ipants, 61.6% (n = 1875) agreed to provide saliva samples
prior to start of treatment (44 samples of which were not
useable and ﬁve were lost in the post; see [47] for details)
and 51.1% (n = 1556) had complete baseline data and ful-
ﬁlled inclusion and exclusion criteria, and thus constitute
the analytical sample. In addition to providing saliva sam-
ples, participants also completed questionnaires to assess
socio-demographic, smoking, health-related and treatment
characteristics prior to start of treatment (questionnaires
and anonymized data sets generated and/or analysed dur-
ing the current study are available from the corresponding
author on request). The study received ethical approval
from the South East Scotland Research Ethics Committee
(11/AL/0256) and from the University of Toronto. All par-
ticipants included in this analysis consented to take part
and research complied with the ethical principles on hu-
man research, according to the Declaration of Helsinki.
MEASURES
Outcome variables
Short- and long-term continuous abstinence
Continuous abstinence was assessed at both 4- and 52-
week follow-up post-target quit dates [46]. As per standard
SSS criteria, abstinence at 4-week follow-up was deﬁned as
complete abstinence from smoking in the past 2weeks, ver-
iﬁed by an expired air-carbonmonoxide (CO) reading below
10 parts per million (p.p.m.), conducted at the SSS. As this
study was interested in determining veriﬁed prolonged ab-
stinence, only those participants whowere deﬁned as absti-
nent at 4-week follow-up were followed-up further at
52 weeks. Smoking abstinence was again veriﬁed by CO
reading, conducted at the participantss homes by the mar-
ket research company TNS BMRB. Following recom-
mended practice, participants lost to follow-up were
considered to be still smoking [48].
Explanatory variables
Nicotine metabolite ratio
Saliva samples were collected with Sarstedt Salivettes® and
posted to University College London, where they were
stored in 20°C freezers before being shipped to the Uni-
versity of Toronto or ABS laboratories for analysis. As ear-
lier interlaboratory studies have shown comparable
results among these different laboratories [49,50], which
was also the case in the current study (see [30] for details),
analyses from both laboratories were pooled. As described
previously [30], established liquid chromatography tan-
dem mass spectrometry (LC–MS/MS) methodology with a
1 ng/ml limit of quantiﬁcation (LOQ) [25,50] was used to
determine cotinine (COT) and trans-3HC levels in saliva
samples to calculate the NMR ratio (3HC/COT). Examina-
tion for analytical shift and reliability (conducted on 5%
of samples) showed NMR results to be highly reliable
(R2 = 0.984) with no association between change in
NMR and time between analyses (R2 = 0.004). Given that
NMR may be unstable for occasional and light smokers
[51], samples with cotinine values below the standard
cut-off for smoking (10 ng/ml) were excluded. In cases
where COT values were above 10 ng/ml but 3HC was
below LOQ, the 3HC value was replaced by LOQ divided
by the square root of two to compute the NMR [52]. Based
on population data from the previous prospectively NMR
randomized clinical trial [41], participants in the analytical
sample were classiﬁed into normal (NMR ≥ 0.31;
n = 1105; 71.0%) or slow (NMR < 0.3; n = 451; 29.0%)
metabolizer (see Table 1). Further information on socio-
demographic differences by NMR status has been pub-
lished elsewhere [46].
Pharmacotherapy and behavioural support characteristics
In this observational study, following consultation, partici-
pants chose their treatment freely, and thiswas recorded by
SSS practitioners. Pharmacotherapy was dichotomized
into varenicline or NRT product use (single or combined
NRT). As indicated above, participants with combination
non-NRT/NRT treatment, bupropion or no pharmacother-
apy were excluded from the analysis. The type of behav-
ioural support chosen was also recorded as individual
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(one-to-one; non-group drop-in) versus group-based
(open/rolling groups; closed groups) support. Further
information on socio-demographic differences by treat-
ment characteristics has been published elsewhere [46].
Covariates
Socio-demographic characteristics
Standard socio-demographics [age, sex, socio-economic
status (SES), ethnicity, marital status] were recorded by
SSS staff at baseline. SES was measured with the National
Statistics Socio-economic Classiﬁcation (NSSEC) [53] and
grouped into higher versus lower SES, using the NSSEC
coding ABC1/C2DE (managerial occupations/manual and
unemployed). Due to a relatively small number of
participantswith an ethnicminority background, ethnicity
was split into ‘white British’ and ‘other’.
Stop Smoking Service and smoking characteristics
As local funding rules and policies are likely to affect treat-
ment choice and success rates [54], SSS location was re-
corded and divided into North, Midlands and South
regions of England. At baseline, nicotine dependence was
measured with the Heaviness of Smoking Index (HSI) [55],
classifying participants as having high (HSI score 4–6) or
low dependence (HSI score 0–3) [56]. Determination to quit
was assessed on a one-item four-point Likert scale (ranging
from ‘not at all determined’ to ‘extremely determined’),
andwhether participants had attempted to quit in the previ-
ous 12 months was also recorded (yes/no).







(n = 1488) P
Mean (SD) age 42.5 (14.1) 41.8 (14.1) 43.2 (14.1) 0.004
% (n) Female 55.9 (1701) 52.3 (814) 59.6 (887) < 0.001
% (n) Higher SES (ABC1) 23.4 (712) 23.9 (372) 22.8 (340) 0.494
% (n) White 96.0 (2922) 94.9 (1477) 97.1 (1445) 0.002
% (n) Married/cohabiting 47.0 (1431) 46.7 (727) 47.3 (704) 0.771
% (n) Poor physical health 56.2 (1711) 56.0 (871) 56.5 (840) 0.798
% (n) Poor wellbeing 44.7 (1318) 43.1 (671) 46.5 (647)a 0.064
% (n) Higher dependence score (HSI ≥ 4) 49.4 (1489) 47.8 (743) 51.1 (746)b 0.068
% (n) Past-year quit attempt 41.5 (1237) 40.9 (637) 42.0 (600)c,d 0.552
% (n) Determination to quit < 0.001
Not at all 8.8 (261) 8.4 (131) 9.1 (130)
Very determined 39.5 (1176) 43.0 (669) 35.6 (507)
Extremely determined 51.8 (1542) 48.6 (756) 55.2 (786)e
% (n) Behavioural support < 0.001
Individual support 78.6 (2385) 75.7 (1178) 81.7 (1207)
Group support 21.4 (648) 24.3 (378) 18.3 (270)
% (n) Pharmacological support < 0.001
Single NRTf 17.7 (540) 17.2 (268) 18.3 (272)
Combination NRTg 30.6 (933) 36.9 (574) 24.1 (359)
Varenicline 43.0 (1308) 45.9 (714) 39.9 (594)
Bupropion 0.9 (27) – 1.8 (27)
Varenicline and NRT 4.2 (129) – 8.7 (129)
Other combination 0.2 (5) – 0.3 (5)
None 3.4 (102) – 6.9 (102)
% (n) SSS Region < 0.001
North 50.3 (1532) 44.9 (699) 56.0 (833)
Midlands 38.3 (1166) 41.6 (647) 34.9 (519)
South 11.4 (346) 13.5 (210) 9.1 (136)
Participants with valid saliva sample (n = 1826) (n = 1556) (n = 270)
% (n) Slow metabolizers 28.5 (520) 29.0 (451) 25.6 (69) 0.273
SES = socio-economic status; HSI =Heaviness of Smoking Index; NRT= nicotine replacement therapy; SSS = Stop Smoking Services; SD= standard deviation.
a98 cases missing; b29 cases missing; c61 cases missing; d65 cases missing; e11 cases missing; fsingle NRT products used were patches (n = 361; 66.9%), in-
halator (n = 64; 11.9%), lozenges (n = 64; 11.9%), gum (n = 26; 4.8%), nasal/mouth spray (n = 23; 4.3%) and minitabs (n = 2; 0.4%); gcombination NRT
most commonly involved patch together with inhalator (n = 289; 31.0%), lozenge (n = 182; 19.5%), nasal/mouth spray (n = 153; 16.4%) or gum (n = 85;
9.1%) and approximately 16% (n = 178) used more than two NRT products concurrently.
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Health-related characteristics
Participants were asked to provide information about any
medical conditions, and those with at least one condition
were coded as having poorer physical health compared
with those without. Participants also completed the
World Health Organization (WHO)-5 wellbeing index [57],
a tool used in primary care to determine psychological
wellbeing using ﬁve questions scored from 0 to 5, with
higher scores indicating better quality of life. Scores were
summated and converted into a percentage of the maxi-
mum score [25], with scores ≤ 50% indicating low subjec-
tive wellbeing [58].
Analyses
In univariate analyses, group differences between the ana-
lytical and excluded samples in socio-demographic,
smoking, health-related, NMR and treatment characteris-
tics and smoking outcomes were assessed using χ2/t-tests
for categorical/continuous variables, respectively. Multivar-
iable log-binomial generalized linear models were used to
provide risk ratios (RR). Analyses tested the independent
relationships between smoking outcomes at 4-week and
12-month follow-up and predictors, including a pharma-
cotherapy choice (NRT versus varenicline) by NMR status
(slow versus normal NMR) interaction term to determine
whether treatment effectiveness varied as a function of nic-
otine metabolism as well as their respective main effects,
adjusting for covariates in Table 1. Age was transformed
using the standard deviation of the variable as the scaling
factor, as it did not meet linearity assumptions [59]. Due
to insufﬁcient numbers, SSS location was not modelled as
a random effect but included as a covariate in analysis. In
sensitivity analyses, NMR status was deﬁned based on
quartiles to classify slow (1st quartile) versus fast (4th
quartile) metabolizers or NMRwas entered as a continuous
variable. Bayes factors (BF) were also calculated for the pri-
mary analysis using standard cut-offs to conﬁrm ﬁndings
and determine whether results can be interpreted as evi-
dence to support the null-hypothesis (BF< 1/3), the alter-
native hypothesis (BF > 3) or whether data were inclusive
(BF<>1/3 and< 3). This was based on detectingan effect
equivalent to the clinical trial data [41] using standard
methodologywith a half-normal distribution andmean dif-
ference parameter estimates to represent the alternative
hypothesis [60]. Furthermore, given that previous clinical
work had compared only the relative effectiveness of NRT
patch versus varenicline among slow and normal
metabolizers [41] the sample was restricted to users of
these speciﬁc pharmacotherapies in sensitivity analysis.
Lastly, as the uptake of group versus individual support
has been shown to differ as a function of NMR status
[30], a higher-order interaction term (behavioural sup-
port × NMR status × pharmacotherapy) in addition to
lower-order interaction terms, and main effects was in-
cluded in the main model to assess robustness of ﬁndings.
RESULTS
As shown in Table 1, the analytical sample (n = 1556) was
somewhat younger, less likely to be female, white, to be ex-
tremely determined to quit or from the North of England
than the excluded sample. They were also more likely to
use group support. However, NMR status did not differ be-
tween those participants in the analytical and excluded
samples who had provided saliva (Table 1). At 4-week
follow-up, 44.2% [95% conﬁdence interval (CI) = 41.7–
46.6%] of participants were veriﬁed as continuously absti-
nent; this rate dropped to 8.0% (95% CI = 6.8–9.5%) at
the 12-month follow-up. Figure 1 shows the raw absti-
nence rates broken down by type of pharmacotherapy used
and NMR status (Supporting information, Fig. S1 presents
adjusted data).
Does NMR status moderate the short- and long-term
effectiveness of nicotine compared with non-nicotine
pharmacotherapy in SSS?
The effect of pharmacotherapy on outcomes did not appear
to be moderated by NMR status. This was conﬁrmed in ad-
justed analysis. There was no interaction of NMR status by
pharmacotherapy choice on either 4- or 52-week follow-
ups when controlling for all other variables (see Table 2).
Bayes factors indicated that for the 4-week follow-up there
was no effect (BF = 0.25) but that for the 52-week follow-
up data were inconclusive (BF = 0.73). Given the lack of a
support for the alternative hypothesis, the interaction term
was therefore removed for the analyses below. Greater ab-
stinence rates at 4- and 52-week follow-up were indepen-
dently associated with lower dependence and being
married or cohabiting. Higher socio-economic status and
use of varenicline were also associated with greater absti-
nence rates at 4-week follow-up but only marginally so at
52-week follow-up (Table 2). In addition, older age, greater
Figure 1 Raw continuous abstinence rates by pharmacotherapy type
and nicotine metabolite ratio (NMR) status (n = 1556)
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determination to quit, using group support and attending
SSS in the North or Midlands region of England were
associated with greater abstinence rates only at 4-week
follow-up.
Are results consistent across different operationalizations
of NMR or when restricting pharmacotherapy to
varenicline and transdermal nicotine patch alone?
Further sensitivity analyses were conducted to assess the
robustness of ﬁndings. Characterizing participants into
slow versus fast metabolizers based on quartiles or using
NMR as a continuous variable did not affect the observed
associations, or lack thereof. Similarly, restricting the
sample to NRT patch and varenicline users only did not
alter results materially (see Supporting information,
Tables S1–S3).
Is the relationship between smoking cessation outcomes,
NMR status and pharmacotherapy moderated by the type
of behavioural treatment received?
Lastly, a higher-order interaction was included in the sensi-
tivity analysis to determine whether or not the putative ef-
fect of NMR status on pharmacotherapy effectiveness is
dependent on the type of behavioural support provided.
This was considered, at least in part, as we had previously
observed self-selection of group support by NMR, where
normal metabolizers were less likely to use group support
[30]. Behavioural support choice moderated the impact
of the NMR status by pharmacotherapy choice relationship
on the 52-week (Wald χ2 = 6.33, P = 0.012) but not 4-
week follow-up abstinence rates. As can be seen in Fig. 2,
the relative beneﬁt of varenicline over NRT at 52-week
follow-up was greater in slowmetabolizers receiving group
rather than individual support (adjusted RR for interaction
11.3, 95% CI =1.76–71.7, P = 0.011), whereas this was
not the case for normal metabolizers (adjusted RR for
interaction 0.71, 95% CI = 0.25–2.02, P = 0.515). These
results were not altered materially when including addi-
tional covariate–exposure interactions for two established
determinants for smoking cessation, nicotine dependence
and social grade [61].
DISCUSSION
This study set out to evaluate whether NMR status mod-
erates the impact of NRT relative to varenicline on
smoking cessation rates in a general population sample
of treatment-seeking smokers. Contrary to previous
clinical work [41], we did not observe a beneﬁt of
varenicline over NRT for normal metabolizers compared
with slow metabolizers. We also did not ﬁnd any differ-
ences in abstinence rates between normal and slow
metabolizers when controlling for other known con-
founders. In agreement with previous work [42,61,62],
greater abstinence rates were associated with lower de-
pendence and living together with a partner and, to a
lesser degree, with social grade as well as treatment with
varenicline rather than NRT. Short-term abstinence only
was also associated with older age, determination to quit
and group rather than individual support, as has been
previously shown [54,63].
Several reasons may account for the failure to replicate
clinical trial ﬁndings in this real-world study. First, this
may be due to differences in the socio-demographic com-
position of the type of participants included in clinical tri-
als and population studies. Clinical trials often exclude
smokers with comorbidities such as mental health issues
and may attract more proactive participants, motivated
by ﬁnancial remuneration. The NMR-based clinical trial
also excluded individuals taking drugs which were known
inhibitors of CYP2A6, which could transiently (or longer)
convert a normal metabolizer to a slow metabolizer [41].
By contrast, our study passively recruited all smokers at-
tending stop smoking services, who were not reimbursed
for participation. Secondly, and relatedly, given ethnic var-
iation in NMR [27], our results may reﬂect genuine differ-
ences in UK versus North American smokers, where the
current trial was 95% white, which was substantially
lower (55% white) in the North American trial [41].
Thirdly, while clinical trials have high internal validity
assessing efﬁcacy of treatments with high ﬁdelity and good
implementation, they lack the external validity of popula-
tion studies which assess treatment effectiveness outside a
controlled environment, with suboptimal implementation.
Fourthly, clinical trials will seek to maximize follow-up re-
sponse to obtain an accurate estimate of the treatment ef-
fect, whereas follow-up rates in population studies such as
ours tend to be lower, leading to potential underestimates
of treatment effects in the context of intention-to-treat
analysis. Fifthly, compliance was not assessed, and it is
Figure 2 Adjusted continuous 52-week veriﬁed abstinence rates
based on estimated marginal means by pharmacotherapy and behav-
ioural support type and nicotine metabolite ratio (NMR) status
(n = 1556)
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difﬁcult to compare drug effects if compliance differs. The
NRT arms differed substantially, with the majority of NRT
users being dual users while the previous clinical trial
used only transdermal patch. It is possible that dual NRT
is as useful for normal metabolizers as varenicline. Lastly,
and importantly, whereas in clinical trials participants are
randomly allocated to treatment, smokers in our study
self-selected their treatment and normal metabolizers
were less likely to use group support (see limitations be-
low). Although we controlled for a range of covariates,
the difference in this study and the previous clinical trial
may in part, therefore, reﬂect confounding due to factors
not accounted for.
While we did not detect the predicted interaction of
NMR status with pharmacotherapy type on smoking ces-
sation outcomes, we observed an association of NMR sta-
tus with pharmacotherapy effectiveness as a function of
the behavioural support provided. Speciﬁcally, the effective-
ness of varenicline over NRT was markedly more pro-
nounced in the context of group rather than individual
behavioural support, but only for slow and not normal
metabolizers. It should be acknowledged that this ﬁnding
needs to be interpreted with caution, given small numbers.
Individual support is more commonly accessed via com-
munity practitioners (e.g. general practitioners, pharma-
cists) who provide shorter and fewer counselling sessions,
whereas group support is almost exclusively accessed via
specialist stop smoking clinics which provide more inten-
sive, longer treatment, often over six to eight face-to-face
sessions [46]. Given that varenicline has aworse side-effect
proﬁle for slow rather than normal metabolizers [41], slow
metabolizers may discontinue varenicline earlier in the
context of individual support, with less intensive support
and limited advice on medication adherence. By contrast,
being provided with more extensive advice on medication
side effects and the importance of adherence in the context
of group support, slow metabolizers may be more likely to
continue treatment with varenicline, resulting in superior
outcomes. This would be less of an issue for normal
metabolizers who experience fewer side-effects.
This study has a number of limitations. As previously
mentioned, participants self-selected their treatment, and
thus ﬁndings may be the result of an artefact due to con-
founding. Although we controlled for a range of potentially
important covariates, not all putative factors (including
medication adherence) were measured and some variables
were only assessed with a single item. In particular, as re-
ported previously, normal metabolizers were less likely to
choose group behavioural support [30], which appears to
affect pharmacotherapy outcome in this analysis. While
the longitudinal design allowed us to investigate temporal
effects, it resulted in high levels of attrition and relatively
small numbers of smokers who had quit by the end of the
study, limiting our power to detect more complex effects.
Moreover, even though we used a prospective design, this
does not allow us to make causal claims. Finally, while
the initial sample collected was largely representative of
smokers seeking treatment in the United Kingdom, there
were some marked demographic and treatment differences
between those who had complete data and were included
in the analysis and those who were excluded. Findings
may therefore not generalize beyond the current sample.
CONCLUSIONS
Our study did not replicate clinical trial data, suggesting
that NMR status of treatment-seeking smokers does not
contribute substantially to differential pharmacotherapy
effectiveness in Stop Smoking Services, when both phar-
macotherapy and behavioural support are self-selected.
While there may be a number of reasons for this, one po-
tential explanation for this ﬁnding is the distinctly different
effect that varying levels of behavioural support may have
on treatment with NRT and varenicline for slow versus
normal metabolizers. If correct, and corroborated by fur-
ther studies, this interpretation would have clear implica-
tions for treatment delivery to slow and normal
metabolizers: the beneﬁts of varenicline over NRT previ-
ously identiﬁed may only become apparent for slow
metabolizers if sufﬁcient behavioural support is provided.
Altogether, our results suggest that NMR status may not
have a large effect on real-world self-selected treatment
outcomes and that the impact of NMR may be context-
dependent. While this suggests one potential reason for
the apparent discordance in the literature, further clariﬁca-
tion of the role of the rate of nicotine metabolism, choice of
group counselling and their interaction with treatment ef-
fect is required. Speciﬁcally, it will be important to under-
stand (1) whether dual NRT behaves in the same way as
transdermal NRT alone with respect to NMR predicting
outcomes in the context of clinical trials and (2) the impact
of the type of counselling (and associated treatment adher-
ence) on NMR status by pharmacotherapy effects in the
context of real-world settings where treatment choice is
based on NMR status, which is prescriber-selected rather
than self-selected.
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